Entities / Company
Verve Therapeutics.
American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.Some support6 reports
-
FDA granted Fast Track designation for Verve-102 on July 11, 2025, coinciding with Lilly's acquisition announcement that surged Verve's stock.Some support5 reports
-
BMO Capital downgraded Verve Therapeutics' stock rating to Market Perform on June 27, 2025.Speculative1 report
-
Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Verve Therapeutics this week
News at the entities that move Verve Therapeutics most-
FDA StructuralFDA rated generic equivalent to brand Climara Pro.Moves Verve Therapeutics
-
Cantor Fitzgerald OperationalTD Cowen reaffirmed a buy rating while Cantor Fitzgerald downgraded monday.com Ltd. on October 6, 2026.Moves Verve Therapeutics
-
Eli Lilly and Company TransactionalMedicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Moves Verve Therapeutics
Connections
The 4 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Sekar Kathiresan Structural
Sekar Kathiresan is the co-founder and CEO of Verve Therapeutics.
-
FDA Structural
The FDA formally regulates and approves drugs developed by Verve Therapeutics, determining their market viability.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald's rating upgrades and recommendations actively influence Verve Therapeutics' stock performance.
-
Eli Lilly and Company Transactional
Verve Therapeutics was acquired by Eli Lilly and Company to strengthen Lilly's gene therapy and editing pipeline.
History
Events by the month they beganJune 2026
4 events- Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.
- FDA granted Fast Track designation for Verve-102 on July 11, 2025, coinciding with Lilly's acquisition announcement that surged Verve's stock.
- BMO Capital downgraded Verve Therapeutics' stock rating to Market Perform on June 27, 2025.
- Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.